Associated Papers
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study.
Varela M et al.
Translational Lung Cancer Research, 2025
40386732 (PubMed )
Supplement: tlcr-14-04-1254-supplementary.pdf
Diverse clinical outcomes for the EGFR‑mutated and ALK‑rearranged advanced non‑squamous non‑small cell lung cancer.
Lin CW et al.
Oncology Letters, 2025
39807107 (PubMed )
Supplement: Supplementary_Data2.pdf
The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer.
Szpechcinski A et al.
International Journal of Molecular Sciences, 2024
39063150 (PubMed )
Supplement: ijms-25-07908-s001.zip › ijms-3103240-supplementary.pdf
Atypical Droplet Digital Polymerase Chain Reaction Patterns That Indicate Uncommon but Clinically Actionable EGFR Mutations in Lung Cancer.
Lechner A et al.
Archives of Pathology & Laboratory Medicine, 2024
Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer.
Akkhasutthikun P et al.
Cancer Research and Treatment, 2024
37986562 (PubMed )
Supplement: crt-2023-1108-Supplementary-Table-S10.pdf
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
38496837 (PubMed )
Supplement: mmc1.xlsx › Sheet1
Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.
Saito A et al.
Cancer Medicine, 2024
38457233 (PubMed )
Supplement: CAM4-13-e7077-s003.xlsx › Table_S5
Evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed, paraffin-embedded tissue of human lung cancer.
Xu Y et al.
Journal of Thoracic Disease, 2024
Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology-Based EGFR Mutation Assay in Patients with Operable Non-Small Cell Lung Cancer.
Park IH et al.
Cancer Research and Treatment, 2024
37340844 (PubMed )
Supplement: crt-2023-408_S1_Table.pdf
Comparison and Validation of Rapid Molecular Testing Methods for Theranostic Epidermal Growth Factor Receptor Alterations in Lung Cancer: Idylla versus Digital Droplet PCR.
Léonce C et al.
International Journal of Molecular Sciences, 2023
37958668 (PubMed )
Supplement: ijms-24-15684-s001.zip › ijms-2676079_-_Supplementary_Figures_S1-S5.pdf
Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma.
Casula M et al.
International Journal of Molecular Sciences, 2023
37047382 (PubMed )
Supplement: ijms-24-06410-s001.zip › ijms-2177723-supplementary.pdf
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_3.xlsx › EGFR_mutations
Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.
Bhai P et al.
Frontiers in Oncology, 2023
37483495 (PubMed )
Supplement: Table_2.xlsx › all_patients_lung
Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant.
Soon Jian Hao J et al.
Cold Spring Harbor Molecular Case Studies, 2022
36577523 (PubMed )
Supplement: supp_mcs.a006223_Supplemental_Material.pdf
Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples.
Gumà J et al.
Cancers, 2022
36497340 (PubMed )
Supplement: cancers-14-05859-s001.zip › cancers-2069645-supplementary.pdf
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing.
Lee J et al.
Journal of Pathology and Translational Medicine, 2022
36128861 (PubMed )
Supplement: jptm-2022-06-11-suppl1.pdf
The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors.
Lee H et al.
Cancers, 2022
35740676 (PubMed )
Supplement: cancers-14-03011-s001.zip › cancers-1735308-supplementary.pdf
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
35244186 (PubMed )
Supplement: Supplementary_Data2.xlsx › Feuil1
Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing.
Nkosi D et al.
Genes, 2022
35627184 (PubMed )
Supplement: genes-13-00799-s001.zip › genes-1613678-supplementary.pdf
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
Adib E et al.
Genome Medicine, 2022
35428358 (PubMed )
Supplement: 13073_2022_1041_MOESM2_ESM.xlsx › S2_EGFR_Druggable
Clinical and genomic features of Chinese lung cancer patients with germline mutations.
Peng W et al.
Nature Communications, 2022
35273153 (PubMed )
Supplement: 41467_2022_28840_MOESM7_ESM.xlsx › Sheet1
An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy.
Lin J et al.
Frontiers in Immunology, 2022
36505399 (PubMed )
Supplement: Table_2.xlsx › vars
NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report.
Wang H et al.
Frontiers in Oncology, 2022
Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR.
Ntzifa A et al.
Cancers, 2021
34073111 (PubMed )
Supplement: cancers-13-02736-s001.zip › cancers-1192044-supplementary.pdf
Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers.
Gilson P et al.
Scientific Reports, 2021
34006948 (PubMed )
Supplement: 41598_2021_90091_MOESM2_ESM.pdf
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
33704917 (PubMed )
Supplement: TCA-12-1271-s003.xls › Foglio1
Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study.
Lamy PJ et al.
Cancers, 2020
33081150 (PubMed )
Supplement: cancers-12-03002-s001.pdf
Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate.
Arcila ME et al.
Jto Clinical and Research Reports, 2020
33511359 (PubMed )
Supplement: mmc1.docx
A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.
Torres S et al.
Expert Review of Molecular Diagnostics, 2020
Rapid EGFR mutation testing in lung cancer tissue samples using a fully automated system and single-use cartridge.
Al-Turkmani MR et al.
Practical Laboratory Medicine, 2020
Variation in nomenclature of somatic variants for selection of oncological therapies: Can we reach a consensus soon?
Keppens C et al.
Human Mutation, 2020
31553104 (PubMed )
Supplement: HUMU-41-7-s001.pdf
Major challenges in accurate mutation detection of multifocal lung adenocarcinoma by next-generation sequencing.
Qiu T et al.
Cancer Biology & Therapy, 2020
Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic.
Freitas HC et al.
Frontiers in Oncology, 2020
32714871 (PubMed )
Supplement: Data_Sheet_1.XLSX › Panel_-_Tumor_Tests
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
31795195 (PubMed )
Supplement: cancers-11-01895-s001.zip › ICC_ctDNA_Cancers_Supplementary_Table_5._50_cancer_gene_panel_information.xlsx › cms_106003
Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.
Evrard SM et al.
The Journal of Molecular Diagnostics : Jmd, 2019
De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors.
Li JW et al.
Cancer Biology & Therapy, 2019
Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q et al.
Molecular Cancer, 2018
30153823 (PubMed )
Supplement: 12943_2018_875_MOESM5_ESM.xlsx › Table_S4_Tissue_DNA_Mutation
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
30064409 (PubMed )
Supplement: 12894_2018_380_MOESM1_ESM.xlsx › Supplementary_Table_1
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
29161613 (PubMed )
Supplement: mmc1.xlsx › Supplementary_Table_1
Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients.
Su J et al.
Oncotarget, 2017
Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
Li SD et al.
Genome Medicine, 2017
29082853 (PubMed )
Supplement: 13073_2017_478_MOESM1_ESM.xlsx › Table_S2
Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma.
Xu T et al.
Theranostics, 2017
28529628 (PubMed )
Supplement: thnov07p1437s1.pdf
Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population.
Berois N et al.
Journal of Cancer Epidemiology, 2017
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.
Lai Z et al.
Nucleic Acids Research, 2016
27060149 (PubMed )
Supplement: gkw227_Supplementary_Data.zip › nar-03544-met-k-2015-File003.xls › Suppl._Table_3
Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).
De Grève J et al.
Plos One, 2016
1–50 of 59 papers
Select a paper to view details